Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats

Halil İbrahim Öksüz; Hale Öksüz; Ali Üçkayabaşı; Işıl Ocal

doi:10.12991/jrespharm.1950209

Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats

Abstract

This study evaluated changes in motor nerve conduction velocity (MNCV) over a four-week follow-up period in non-diabetic and diabetic rats exposed to systemic rotenone and investigated the potential modulatory effect of pulsed magnetic field (PMF) application. Eight experimental groups were included: control (C), control+PMF (C+PMF), control+rotenone (C+ROT), control+rotenone+PMF (C+ROT+PMF), diabetes mellitus (DM), diabetes mellitus+PMF (DM+PMF), diabetes mellitus+rotenone (DM+ROT), and diabetes mellitus+rotenone+PMF (DM+ROT+PMF). The final analysis included 80 rats, with 10 animals in each group. MNCV was measured at study baseline and at the end of weeks 1, 2, 3, and 4. Rotenone-treated animals were also monitored qualitatively for Parkinsonian-like motor signs. Rotenone exposure was associated with a progressive reduction in MNCV. Compared with the C group, MNCV was significantly lower in the C+ROT group from week 1 through week 4. Similarly, MNCV was significantly lower in the DM+ROT group than in the DM group during weeks 2–4. MNCV was significantly higher in the C+PMF group than in the C group at week 4 and in the DM+PMF group than in the DM group during weeks 2–4. No significant differences were detected between the C+ROT and C+ROT+PMF groups or between the DM+ROT and DM+ROT+PMF groups at any measurement time. Overall, systemic rotenone exposure was associated with impaired peripheral motor nerve conduction in both non-diabetic and diabetic rats. The applied PMF protocol was associated with time-dependent changes in MNCV under non-rotenone conditions but did not significantly attenuate rotenone-associated impairment in peripheral motor nerve conduction.

Keywords

Supporting Institution

Cukurova University

Project Number

TDK-2025-17162

Ethical Statement

This study was approved by the Cukurova University Animal Experiments Local Ethics Committee (Date: 26.09.2024, Decision No.4).

References

[1] Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015; 386(9996): 896-912. https://doi.org/10.1016/S0140-6736(14)61393-3
[2] Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017; 3: 17013. https://doi.org/10.1038/nrdp.2017.13
[3] Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE. A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol. 2024; 23(2): 191-204. https://doi.org/10.1016/S1474-4422(23)00404-0
[4] Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000; 3(12): 1301-1306. https://doi.org/10.1038/81834
[5] Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE, Greenamyre JT. A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis. 2009; 34(2): 279-290. https://doi.org/10.1016/j.nbd.2009.01.016
[6] Van Laar AD, Webb KR, Keeney MT, Van Laar VS, Zharikov A, Burton EA, Hastings TG, Glajch KE, Hirst WD, Greenamyre JT, Rocha EM. Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathy. NPJ Parkinsons Dis. 2023; 9(1): 121. https://doi.org/10.1038/s41531-023-00561-6
[7] Binienda ZK, Sarkar S, Mohammed-Saeed L, Gough B, Beaudoin MA, Ali SF, Paule MG, Imam SZ. Chronic exposure to rotenone, a dopaminergic toxin, results in peripheral neuropathy associated with dopaminergic damage. Neurosci Lett. 2013; 541:233-237. https://doi.org/10.1016/j.neulet.2013.02.047
[8] Sarkar S, Gough B, Raymick J, Beaudoin MA, Ali SF, Virmani A, Binienda ZK. Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: Neuroprotective effects of acetyl-L-carnitine. Neurosci Lett. 2015; 606:53-59. https://doi.org/10.1016/j.neulet.2015.08.044

[9] Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nat Rev Dis Primers. 2019; 5(1): 41. https://doi.org/10.1038/s41572-019-0092-1
[10] Elafros MA, Andersen H, Bennett DL, Savelieff MG, Viswanathan V, Callaghan BC, Feldman EL. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022; 21(10): 922-936. https://doi.org/10.1016/S1474-4422(22)00188-0
[11] Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X, Luo Z, Hu J, Peng S. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. Front Endocrinol (Lausanne). 2023; 14: 1265372. https://doi.org/10.3389/fendo.2023.1265372
[12] Coppey LJ, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. Int J Exp Diabetes Res. 2000; 1(2): 131-143. https://doi.org/10.1155/EDR.2000.131
[13] Zhong Q, Wang S. Association between diabetes mellitus, prediabetes and risk, disease progression of Parkinson's disease: a systematic review and meta-analysis. Front Aging Neurosci. 2023; 15: 1109914. https://doi.org/10.3389/fnagi.2023.1109914
[14] Bantounou MA, Shoaib K, Mazzoleni A, Modalavalasa H, Kumar N, Philip S. The association between type 2 diabetes mellitus and Parkinson’s disease: a systematic review and meta-analysis. Brain Disord. 2024; 15: 100158. https://doi.org/10.1016/j.dscb.2024.100158
[15] Salem EA, Alqahtani SM, El-Shoura EAM, Zaghlool SS, Abdelzaher LA, Mohamed SAM, Alalhareth IS, Sheref AAM. Neuroprotective effects of semaglutide and metformin against rotenone-induced neurobehavioral changes in male diabetic rats. Naunyn Schmiedebergs Arch Pharmacol. 2025; 398(9):11919-11931. https://doi.org/10.1007/s00210-025-03920-7
[16] De Pedro JA, Pérez-Caballer AJ, Domínguez J, Collía F, Blanco J, Salvado M. Pulsed electromagnetic fields induce peripheral nerve regeneration and endplate enzymatic changes. Bioelectromagnetics. 2005; 26(1): 20-27. https://doi.org/10.1002/bem.20049
[17] Weintraub MI, Herrmann DN, Smith AG, Backonja MM, Cole SP. Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. Arch Phys Med Rehabil. 2009; 90(7): 1102-1109. https://doi.org/10.1016/j.apmr.2009.01.019
[18] Battecha K. Efficacy of pulsed electromagnetic field on pain and nerve conduction velocity in patients with diabetic neuropathy. Bull Fac Phys Ther. 2017; 22(1): 9-14. https://doi.org/10.4103/1110-6611.209877
[19] Tassone EE, Page JC, Slepian MJ. Assessing the effects of pulsed electromagnetic therapy on painful diabetic distal symmetric peripheral neuropathy: a double-blind randomized controlled trial. J Diabetes Sci Technol. 2025; 19(2): 361-369. https://doi.org/10.1177/19322968231190413
[20] Zis P, Grünewald RA, Chaudhuri RK, Hadjivassiliou M. Peripheral neuropathy in idiopathic Parkinson’s disease: a systematic review. J Neurol Sci. 2017; 378: 204-209. https://doi.org/10.1016/j.jns.2017.05.023
[21] Corrà MF, Vila-Chã N, Sardoeira A, Hansen C, Sousa AP, Reis I, Sambayeta F, Damásio J, Calejo M, Schicketmueller A, Laranjinha I, Salgado P, Taipa R, Magalhães R, Correia M, Maetzler W, Maia LF. Peripheral neuropathy in Parkinson’s disease: prevalence and functional impact on gait and balance. Brain. 2023; 146(1): 225-236. https://doi.org/10.1093/brain/awac026
[22] Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology. 2015; 46: 101-116. https://doi.org/10.1016/j.neuro.2014.12.002
[23] Miyazaki I, Asanuma M. The rotenone models reproducing central and peripheral features of Parkinson’s disease. NeuroSci. 2020; 1(1): 1-14. https://doi.org/10.3390/neurosci1010001
[24] Lei T, Jing D, Xie K, Jiang M, Li F, Cai J, Wu X, Tang C, Xu Q, Liu J, Guo W, Shen G, Luo E. Therapeutic effects of 15 Hz pulsed electromagnetic field on diabetic peripheral neuropathy in streptozotocin-treated rats. PLoS One. 2013; 8(4): e61414. https://doi.org/10.1371/journal.pone.0061414
[25] Mert T, Gunay I, Ocal I. Neurobiological effects of pulsed magnetic field on diabetes-induced neuropathy. Bioelectromagnetics. 2010; 31(1): 39-47. https://doi.org/10.1002/bem.20524
[26] Mert T, Gisi G, Celik A, Baran F, Uremis MM, Gunay I. Frequency-dependent effects of sequenced pulsed magnetic field on experimental diabetic neuropathy. Int J Radiat Biol. 2015; 91(10):833–842. https://doi.org/10.3109/09553002.2015.1068460
[27] Graak V, Chaudhary S, Bal BS, Sandhu JS. Evaluation of the efficacy of pulsed electromagnetic field in the management of patients with diabetic polyneuropathy. Int J Diabetes Dev Ctries. 2009; 29(2): 56-61. https://doi.org/10.4103/0973-3930.53121
[28] Musaev AV, Guseinova SG, Imamverdieva SS. The use of pulsed electromagnetic fields with complex modulation in the treatment of patients with diabetic polyneuropathy. Neurosci Behav Physiol. 2003; 33(8): 745-752. https://doi.org/10.1023/A:1025184912494
[29] Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. J Rehabil Med. 2010; 42(4): 289-295. https://doi.org/10.2340/16501977-0554
[30] Markov MS. Expanding use of pulsed electromagnetic field therapies. Electromagn Biol Med. 2007; 26(3): 257-274. https://doi.org/10.1080/15368370701580806
[31] Tastekin B, Pelit A, Polat S, Tuli A, Sencar L, Alparslan MM, Daglioglu YK. Therapeutic potential of pterostilbene and resveratrol on biomechanic, biochemical, and histological parameters in streptozotocin-induced diabetic rats. Evid Based Complement Alternat Med. 2018; 2018:9012352. https://doi.org/10.1155/2018/9012352
[32] Samarghandian S, Azimi-Nezhad M, Farkhondeh T. Catechin treatment ameliorates diabetes and its complications in streptozotocin-induced diabetic rats. Dose Response. 2017; 15(1):1559325817691158. https://doi.org/10.1177/1559325817691158
[33] Ablat N, Lv D, Ren R, Xiaokaiti Y, Ma X, Zhao X, Sun Y, Lei H, Xu J, Ma Y, Qi X, Ye M, Xu F, Han H, Pu X. Neuroprotective effects of a standardized flavonoid extract from safflower against a rotenone-induced rat model of Parkinson's disease. Molecules. 2016; 21(9):1107. https://doi.org/10.3390/molecules21091107

Details

Primary Language

English

Subjects

Basic Pharmacology

Journal Section

Research Article

Authors

Halil İbrahim Öksüz ^*
0000-0003-0084-6738
Türkiye

Hale Öksüz
0000-0003-2191-4066
Türkiye

Ali Üçkayabaşı
0000-0001-9650-4286
Türkiye

Işıl Ocal
0000-0002-1787-9002
Türkiye

Publication Date

October 6, 2026

Submission Date

May 13, 2026

Acceptance Date

August 26, 2026

Published in Issue

Year 2026 Volume: 30 Number: 5

DOI

https://doi.org/10.12991/jrespharm.1950209

IZ

https://izlik.org/JA35YS62XG

Cite

RIS / Bibtex

APA

Öksüz, H. İ., Öksüz, H., Üçkayabaşı, A., & Ocal, I. (2026). Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats. Journal of Research in Pharmacy, 30(5), 1213-1224. https://doi.org/10.12991/jrespharm.1950209

AMA

1.Öksüz Hİ, Öksüz H, Üçkayabaşı A, Ocal I. Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats. J. Res. Pharm. 2026;30(5):1213-1224. doi:10.12991/jrespharm.1950209

Chicago

Öksüz, Halil İbrahim, Hale Öksüz, Ali Üçkayabaşı, and Işıl Ocal. 2026. “Effects of Pulsed Magnetic Field on Motor Nerve Conduction Velocity in Non-Diabetic and Diabetic Rotenone-Treated Rats”. Journal of Research in Pharmacy 30 (5): 1213-24. https://doi.org/10.12991/jrespharm.1950209.

EndNote

Öksüz Hİ, Öksüz H, Üçkayabaşı A, Ocal I (October 1, 2026) Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats. Journal of Research in Pharmacy 30 5 1213–1224.

IEEE

[1]H. İ. Öksüz, H. Öksüz, A. Üçkayabaşı, and I. Ocal, “Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats”, J. Res. Pharm., vol. 30, no. 5, pp. 1213–1224, Oct. 2026, doi: 10.12991/jrespharm.1950209.

ISNAD

Öksüz, Halil İbrahim - Öksüz, Hale - Üçkayabaşı, Ali - Ocal, Işıl. “Effects of Pulsed Magnetic Field on Motor Nerve Conduction Velocity in Non-Diabetic and Diabetic Rotenone-Treated Rats”. Journal of Research in Pharmacy 30/5 (October 1, 2026): 1213-1224. https://doi.org/10.12991/jrespharm.1950209.

JAMA

1.Öksüz Hİ, Öksüz H, Üçkayabaşı A, Ocal I. Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats. J. Res. Pharm. 2026;30:1213–1224.

MLA

Öksüz, Halil İbrahim, et al. “Effects of Pulsed Magnetic Field on Motor Nerve Conduction Velocity in Non-Diabetic and Diabetic Rotenone-Treated Rats”. Journal of Research in Pharmacy, vol. 30, no. 5, Oct. 2026, pp. 1213-24, doi:10.12991/jrespharm.1950209.

Vancouver

1.Halil İbrahim Öksüz, Hale Öksüz, Ali Üçkayabaşı, Işıl Ocal. Effects of pulsed magnetic field on motor nerve conduction velocity in non-diabetic and diabetic rotenone-treated rats. J. Res. Pharm. 2026 Oct. 1;30(5):1213-24. doi:10.12991/jrespharm.1950209